Contraindication labelling changes in the United States and Germany

European Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 87-93

  Garbe, Edeltraut ^a   Andersohn, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Contraindications; Drug labelling; Drug safety; Germany; United States

Indexed keywords

ANAGRELIDE; ATROPINE METHYL BROMIDE; BOSENTAN; DRUG METABOLIZING ENZYME; ENOXAPARIN; ETHAMBUTOL; FENTANYL; FLUOROURACIL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUVOXAMINE MALEATE; FONDAPARINUX; HUMAN GROWTH HORMONE; ISOTRETINOIN; ITRACONAZOLE; LEVOMETHADONE; METHADONE; POLYSTYRENESULFONATE SODIUM; RECOMBINANT ALPHA2A INTERFERON; RITONAVIR; TRIHEXYPHENIDYL;

AGE; ARTICLE; BODY WEIGHT; CLASSIFICATION; COMPARATIVE STUDY; DRUG CAPSULE; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG INTERACTION; DRUG LABELING; DRUG METABOLISM; GENERAL ASPECTS OF DISEASE; GERMANY; PHARMACOEPIDEMIOLOGY; PREGNANCY; PRIORITY JOURNAL; TABLET; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG INDUSTRY; DRUG INFORMATION SERVICES; DRUG LABELING; GERMANY; HUMANS; INTERNATIONAL COOPERATION; PHARMACEUTICAL PREPARATIONS; PHARMACOPOEIAS; RISK ASSESSMENT; TIME FACTORS; UNITED STATES;

EID: 33845914592     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0229-5     Document Type: Article

References (30)

1. Murphy S, Roberts R (2006) "Black box" 101: how the food and drug administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 117:34-39
2. US Food and Drug Administration (2006) Guidance for industry. Development and use of risk minimization action plans. http:// www.fda.gov/cder/guidance/ 6358fnl.pdf
3. European Commission (2006) Notice to applicants: a guideline on summary of product characteristics revision 1
4. Reggi V, Balocco-Mattavelli R, Bonati M, Breton I, Figueras A, Jambert E, Kopp C, Montane E, Rago L, Rocchi F (2003) Prescribing information in 26 countries: a comparative study. Eur J Clin Pharmacol 59:263-270
5. US Food and Drug Administration (2006) MedWatch safety information. Safety-related drug labeling changes. http://www.fda.gov/medwatch/safety.htm
6. Thomson PDR (2006) Physicians' desk reference
7. US Food and Drug Administration - Center for Drug Evaluation and Research (2006) Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
8. Drugs.Com (2006) Drug information online. http://www.drugs.com/
9. Code of Federal Regulations §201.57 (1990) Specific requirements on content and format of labeling for human prescription drugs
10. Alloza JL, Lasagna L (1983) A comparison of drug product information in four national compendia. Clin Pharmacol Ther 33:269-277
11. Garbe E, Suissa S (2006) Pharmacoepidemiology. In: Ahrens W, Pigeot I (eds) Handbook of epidemiology. Springer, Berlin, pp 1225-1266
12. Bergman U, Anderssen M, Vaccheri A, Larsen J, Montanaro N (1999) Marked differences in lipid-lowering drug use in Bologna, Italy and Funen, Denmark. Eur Heart J 20:1135
13. Bergman U, Andersen M, Vaccheri A, Bjerrum L, Wettermark B, Montanaro N (2000) Deviations from evidence-based prescribing of non-steroidal anti-inflammatory drugs in three European regions. Eur J Clin Pharmacol 56:269-272
14. Cars O, Molstad S, Melander A (2001) Variation in antibiotic use in the European Union. Lancet 357:1851-1853
15. Fissell RB, Bragg-Gresham JL, Gillespie BW, Goodkin DA, Bommer J, Saito A, Akiba T, Port FK, Young EW (2004) International variation in vitamin prescription and association with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44:293-299
16. Fretheim A, Oxman AD (2005) International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Serv Res 5:21
17. Lagerlov P, Veninga CC, Muskova M, Hummers-Pradier E, Stalsby LC, Andrew M, Haaijer-Ruskamp FM (2000) Asthma management in five European countries: doctors' knowledge, attitudes and prescribing behaviour. Drug Education Project (DEP) group. Eur Respir J 15:25-29
18. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U (1997) Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 53:185-189
19. Sanz EJ, Hernandez MA, Ratchina S, Stratchounsky L, Peire MA, Mestre ML, Horen B, Kriska M, Krajnakova H, Momcheva H, Encheva D, Martinez-Mir I, Palop V (2005) Prescribers' indications for drugs in childhood: a survey of five European countries (Spain, France, Bulgaria, Slovakia and Russia). Acta Paediatr 94:1784-1790
20. Vaccheri A, Bjerrum L, Resi D, Bergman U, Montanaro N (2002) Antibiotic prescribing in general practice: striking differences between Italy (Ravenna) and Denmark (Funen). J Antimicrob Chemother 50:989-997
21. Roots I, Gerloff T, Meisel C, Kirchheiner J, Goldammer M, Kaiser R, Laschinski G, Brockmoller J, Cascorbi I, Kleeberg U, Hildebrandt AG (2004) Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev 36:617-638
22. Sebbag L, Boucher P, Davelu P, Boissonnat P, Champsaur G, Ninet J, Dureau G, Obadia JF, Vallon JJ, Delaye J (2000) Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 69:1524-1527
23. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, Vonhof S, Bickeboller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nurnberg P, Pfreundschuh M, Trumper L, Brockmoller J, Hasenfuss G (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754-3762
24. Bernard S, Neville KA, Nguyen AT, Flockhart DA (2006) Interethnic differences in genetic polymorphisms of CYP2D6 in the U. S. population: clinical implications. Oncologist 11:126-135
25. McCarthy LC, Davies KJ, Campbell DA (2002) Pharmacogenetics in diverse ethnic populations - implications for drug discovery and development. Pharmacogenomics 3:493-506
26. Griffin JP, Weber JC (1985) Voluntary systems of adverse reaction reporting. I. Adverse Drug React Acute Poisoning Rev 4:213-230
27. Griffin JP, Weber JC (1986) Voluntary systems of adverse reaction reporting. II. Adverse Drug React Acute Poisoning Rev 5:23-55
28. Griffin JP (1986) Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharmacol 22 (Suppl 1):83S-100S
29. Begaud B, Martin K, Haramburu F, Moore N (2002) Rates of spontaneous reporting of adverse drug reactions in France. JAMA 288:1588
30. Montori VM, Leung TW, Devereaux PJ, Schunemann HJ, Akl EA, Gafni A, Guyatt GH (2006) Can contraindications compromise evidence-based, patient-centered clinical practice? Can J Clin Pharmacol 13:e92-e101